Summary
Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine.
References
Mulder NH, Postmus PE, Sleijfer DTh, de Vries EGE, Willemse PHB (1985) Phase one study of twice weekly vindesine. Eur J Cancer Clin Oncol 21:1555–1556
Natale RB, Gralla RJ, Wittes R, Golbey R, Young C (1980) Vindesine chemotherapy in lung cancer. Cancer Treat Rev 7 (Suppl):59–63
Osterlind K, Dombernowsky P, Sorensens PG, Hansen HH (1981) Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65:245–248
WHO Handbook for reporting results of cancer treatment WHO offset publication No 48 (1979) The Hague, Nyhoff
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Postmus, P.E., Mulder, N.H., Schipper, D.L. et al. Twice weekly vindesine, a phase II study in lung cancer. J Cancer Res Clin Oncol 113, 99–100 (1987). https://doi.org/10.1007/BF00389975
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00389975